EMA says AstraZeneca clot risk 'very rare' as nations battle Covid surges

Share on facebook
Share on twitter
Share on email
Share on whatsapp

THE HAGUE: The EU’s medicines regulator said Wednesday that blood clots should be listed as a rare side effect of the AstraZeneca jab but the benefits continue to outweigh risks, as several countries battle fresh virus surges amid vaccine shortfalls.

© New Straits Times Press (M) Bhd